Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 71

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 71
---
 of the options and does not necessarily reflect actual proceeds received.

(2) Value realized on vesting is equal to the market price of the underlying shares at vesting and does not necessarily reflect actual proceeds received.

Pension Benefits and Nonqualified Deferred Compensation

Our NEOs do not participate in any pension or nonqualified deferred compensation plans and received no pension benefits or nonqualified deferred compensation during the fiscal year 2024.

Employment Arrangements with Named Executive Officers

This section contains a description of the material terms of the employment arrangements with our NEOs. Our executive officers, other than Drs. Saxonov and Hindson, signed offer letters with us, which provide for at-will employment and set forth other terms of employment, including the initial base salary, target incentive opportunity and the terms of the initial equity grant and in the case of Mr. Taich, severance protections in certain circumstances. In addition, each of our executive officers executed a form of our standard at-will employment, confidential information, invention assignment and arbitration agreement, which includes a non-solicit of employees covenant during employment and for one year following termination.

#### Dr. Saxonov
Dr. Saxonov co-founded our company in 2012 and has not been party to an offer letter with us since our inception. In fiscal year 2024, Dr. Saxonov was entitled to an annual base salary of $551,300, which was increased to $650,000 annualized effective April 1, 2024, and he was eligible to earn an annual target bonus equal to 100% of his eligible base salary. Additionally, Dr. Saxonov is eligible to participate in employee benefit plans that are generally available to other senior executives of our company located in the United States.

#### Mr. Taich
Mr. Taich signed an offer letter with us on August 7, 2024, under which he is entitled to an annual base salary of $500,000. In fiscal year 2024, in addition to his base salary Mr. Taich was eligible to earn an annual target bonus equal to 60% of his eligible base salary. In addition, Mr. Taich is eligible to participate in employee benefit plans that are generally available to other senior executives of our company located in the United States. Pursuant to his offer letter, Mr. Taich would be entitled to a lump sum severance payment equal

#### 10X GENOMICS, INC.612025 PROXY STATEMENT
to six